Checkmate Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting
08 Março 2022 - 6:30PM
Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI)
(“Checkmate”), a clinical stage biotechnology company focused
on developing its proprietary technology to harness the power of
the immune system to combat cancer, today announced that it
will present biomarker data at the 2022 American Association for
Cancer Research (AACR) Annual Meeting taking place in New Orleans,
Louisiana from April 8-13, 2022. An e-poster will be made available
online starting Friday, April 8 at 1:00pm ET.
Poster Presentation Details:
Title: Novel transcriptional signatures
associated with antitumor activity in vidutolimod (vidu)-treated
patients (pts) with anti-PD-1-refractory melanoma and non-small
cell lung cancer
(NSCLC)Presenting Author: Art Krieg,
M.D.Abstract #: LB107Session
Title: Late-Breaking Research: Clinical Research
2Session Date and Time: Tuesday, April 12, 2022,
9:00am - 12:30pm CT Location: New Orleans
Convention Center, Exhibit Halls D-H, Poster Section 17, Poster
Board #1
About Checkmate Pharmaceuticals Checkmate
Pharmaceuticals is a clinical stage biotechnology company focused
on developing its proprietary technology to harness the power of
the immune system to combat cancer. Checkmate Pharmaceuticals’
product candidate, vidutolimod (CMP-001), is an advanced generation
Toll-like receptor 9 (TLR9) agonist, delivered as a biologic
virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key
component, designed to trigger the body’s innate immune system to
attack tumors in combination with other therapies. Information
regarding Checkmate Pharmaceuticals is available at
www.checkmatepharma.com.
Availability of Other Information About Checkmate
Pharmaceuticals
Investors and others should note that we communicate with our
investors and the public using our website
(www.checkmatepharma.com) and our investor relations website
(ir.checkmatepharma.com), including but not limited to: investor
presentations and investor fact sheets, U.S. Securities and
Exchange Commission filings, press releases, public conference
calls and webcasts. The information that Checkmate Pharmaceuticals
posts on these channels and websites could be deemed to be material
information. As a result, we encourage investors, the media, and
others interested in us to review the information that is posted on
these channels, including the investor relations website, on a
regular basis. The contents of our website or these channels, or
any other website that may be accessed from our website or these
channels, shall not be deemed incorporated by reference in any
filing under the Securities Act of 1933.
Forward-Looking Statements
Various statements in this release are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including words such as, but not
limited to, “anticipate,” “believe,” “can,” “could,” “expect,”
“estimate,” “design,” “goal,” “intend,” “may,” “might,”
“objective,” “plan,” “predict,” “project,” “target,” “likely,”
“should,” “will,” and “would,” or the negative of these terms and
similar expressions or words, identify forward-looking statements.
Forward-looking statements are based upon current expectations that
involve risks, changes in circumstances, assumptions, and
uncertainties. These statements include those regarding vidutolimod
(CMP-001), including its development, efficacy and therapeutic
potential and the advancement of our clinical and preclinical
pipeline. Forward-looking statements should not be read as a
guarantee of future performance or results and may not be accurate
indications of when such performance or results will be achieved.
These forward-looking statements are subject to risks and
uncertainties, including those related to the development of our
product candidate, including any delays in our ongoing or planned
preclinical or clinical trials, the results from clinical trials,
including the fact that positive results from a trial may not
necessarily be predictive of the results of future or ongoing
clinical trials, the impact of the ongoing COVID-19 pandemic on our
business, operations, clinical supply and plans, the risks inherent
in the drug development process, the risks regarding the accuracy
of our estimates of expenses and timing of development, our capital
requirements and the need for additional financing, and obtaining,
maintaining and protecting our intellectual property. These and
additional risks are discussed in the sections titled “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” in our Quarterly Report on
Form 10-Q for the nine months ended September 30, 2021 and in our
Annual Report on Form 10-K for the year ending December 31, 2020,
as filed with the Securities and Exchange Commission which are
available on the Securities and Exchange Commission’s website at
www.sec.gov, and as well as discussions of potential risks,
uncertainties and other important factors in our subsequent filings
with the Securities and Exchange Commission. All information in
this press release is as of the date of the release, and Checkmate
undertakes no duty to update this information unless required by
law.
Investor Contact
Rob Dolski
Chief Financial Officer
rdolski@checkmatepharma.com
Media Contact
Karen Sharma
MacDougall Advisors
781-235-3060
ksharma@macdougall.bio
Checkmate Pharmaceuticals (NASDAQ:CMPI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Checkmate Pharmaceuticals (NASDAQ:CMPI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024